With semaglutide-like injectables, those changes might be closer than you think
With this development, Mounjaro has secured its second indication in Korea, following its June 2023 approval for improving glycemic control in adults with type 2 diabetes
Nevertheless, in the past few years, seven randomized phase III clinical trials, which tested other first-line and second-line treatments, in intermediate-stage or advanced-stage HCC patients have not found any obvious OS benefits (Llovet et al., 2015)
Health care providers may prescribe GLP-1s for people who have type 2 diabetes and may benefit from losing weight to help manage a coexisting condition
Ipamorelin is usually called the cleaner option because it releases GH without meaningful appetite, cortisol, or prolactin effects